Compare OPTX & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTX | AMRN |
|---|---|---|
| Founded | 1981 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.4M | 339.8M |
| IPO Year | N/A | 1993 |
| Metric | OPTX | AMRN |
|---|---|---|
| Price | $5.51 | $15.64 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.4M | 80.3K |
| Earning Date | 11-13-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $27,900,395.00 | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.02 | $7.08 |
| 52 Week High | $9.15 | $20.90 |
| Indicator | OPTX | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 56.30 |
| Support Level | $5.68 | $14.38 |
| Resistance Level | $6.49 | $15.33 |
| Average True Range (ATR) | 1.28 | 0.80 |
| MACD | -0.30 | 0.01 |
| Stochastic Oscillator | 9.22 | 83.55 |
Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.